The first therapeutic cancer vaccine of prostate cancer approved by FDA is Sipuleucel-T, which is essentially an autologous ex-vivo dendritic cell-based vaccine, pulsed with a single antigen of prostatic acid phosphatase (PAP) fused to GM-CSF [3, 4]. This evidence concerns the gene ACP3 and prostate carcinoma.